A Bayesian network meta-analysis of comparison of cancer therapeutic vaccines for melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-06-29 / J Eur Acad Dermatol Venereol 2021 Oct;35(10):1976-1986Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications
/in Dendritic Cells, International Publications /von 2021-06-28 / Front Cell Dev Biol 2021;9:686544Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors
/in International Publications, Newcastle Disease Virus /von 2021-06-18 / Saudi J Biol Sci 2021 Oct;28(10):5833-5840Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
/in International Publications, Newcastle Disease Virus /von 2021-06-17 / Mol Cancer Ther 2021 Sep;20(9):1723-1734Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
/in Dendritic Cells, International Publications, Prostate Cancer, Urothelial Carcinoma /von 2021-06-09 / Vaccines (Basel) 2021 Jun;9(6)Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2021-06-04 / Cancers (Basel) 2021 Jun;13(11)A phase I study to evaluate the safety and effectiveness of neoantigen-based personalized dendritic cell vaccine in patients with advanced solid tumors.
/in Dendritic Cells, International Publications /von 2021-06-04 / J Clin Oncol 39, 2021 (suppl 15; abstr e14512)Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes
/in International Publications, Newcastle Disease Virus, Urothelial Carcinoma /von 2021-05-27 / BMC Cancer 2021 May;21(1):625Modulated electro-hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial
/in Hyperthermia, International Publications, Ovarian Cancer /von 2021-05-21 / Exp Ther Med 2021 Jul;22(1):787
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de